HIND Stock — Vyome Holdings, Inc.

Vyome Holdings, Inc. (HIND)

Updated October 16, 2026.

HIND is a Stock. Total return is -100.0% over the past 10 years, 414.2 points behind SPY at 314.2%.

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing therapeutic products for immuno-inflammatory and rare diseases. The company's pipeline includes VT-1953, a topical gel in phase 2 testing for bacterial conjunctivitis and inflammatory acne, and VT-1908, an eye drop candidate for immunoinflammatory eye conditions, along with antifungal products developed through a molecular replacement therapy platform in collaboration with Sun Pharma. The company does not currently distribute dividends and is typical of early-stage pharmaceutical developers focused on pipeline advancement rather than income generation.

HIND performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 10 years, 414.2 points behind SPY at 314.2%. Over the past year its total return — price change plus distributions reinvested — is -63.0%. Its deepest 1-year drawdown was 70.4%.

HIND key facts

Asset type

Stock

Asset class

Equity

Inception date

10/06/2016

Distribution frequency

None

Last close

$1.87 (as of 2026-10-16)

Market cap

$13,124,647

Average volume

11200.0

Payout ratio

0.0%

P/E ratio

1.05

EPS

$1.78

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HIND risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 70.4%.

Who may consider HIND — and who may not

It is a weaker fit for investors who need monthly cash flow (HIND does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HIND

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions